Correction to: Long COVID in children and adolescents

Asadi‐Pooya, Ali A.; Nemati, Hamid; Shahisavandi, Mina; Akbari, Ali; Emami, Amir; Lotfi, Mehrzad; Rostamihosseinkhani, Mahtab; Barzegar, Zohreh; Kabiri, Maryam; Zeraatpisheh, Zahra; Farjoud-Kouhanjani, Mohsen; Jafari, Anahita; Sasannia, Sarvin; Ashrafi, Shayan; Nazeri, Masoume; Nasiri, Sara

doi:10.1007/s12519-022-00588-4

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to our analysis of sociodemographic factors, female sex is associated with a higher likelihood of developing long COVID. This finding is consistent with other published studies that have identified female sex as a significant risk factor for LC-19 [11,[30][31][32][33][34]. Moreover, the impact of female sex appears to be uniform across all types of LC-19 patients, as illustrated in Supplementary Fig.…”

Section: Discussionsupporting

confidence: 92%

Identifying Risk Factors and Predicting Long COVID in a Spanish Cohort

Teruel,

Andreu,

Reina

et al. 2024

Preprint

View full text Add to dashboard Cite

Many studies have investigated symptoms, comorbidities, demographic factors, and vaccine effectiveness in relation to long COVID (LC-19) across global populations. However, a number of these studies have shortcomings, such as inadequate LC-19 categorisation, lack of sex disaggregation, or a narrow focus on certain risk factors like symptoms or comorbidities alone. We address these gaps by investigating the demographic factors, comorbidities, and symptoms present during the acute phase of primary COVID-19 infection among patients with LC-19 and those who experienced reinfection, comparing them to typical COVID-19 patients. Additionally, we assess the impact of COVID-19 vaccination on these patients. Drawing on data from the Regional Health System of the Region of Murcia in southeastern Spain, our analysis includes comprehensive information from clinical and hospitalisation records, symptoms, and vaccination details of over 675126 patients across 10 hospitals.We calculated age and sex-adjusted odds ratios (AOR) to identify protective and risk factors for LC-19. Our findings reveal distinct symptomatology, comorbidity patterns, and demographic characteristics among patients with LC-19 versus those with typical COVID-19. Notably, factors such as age, female sex (AOR = 1.39, adjusted p <0.001), symptoms such as chest pain (AOR >1.55, adjusted p <0.001) or hyposmia (AOR >1.5, adjusted p <0.001) and being vaccinated (AOR = 0.10, adjusted p <0.001) significantly influence the risk of LC-19. Interestingly, symptoms and comorbidities show no significant differences when disaggregated by type of LC-19 patient. Vaccination before infection is the most important factor and notably decreases the likelihood of long COVID. Particularly, mRNA vaccines offer more protection against developing LC-19 than viral vector-based vaccines (AOR = 0.48). Additionally, we have developed a model to predict LC-19 that incorporates all studied risk factors, achieving a balanced accuracy of 73% and ROC-AUC of 0.80. This model is available as a free online LC-19 calculator, accessible at (LC-19 Calculator).

show abstract

Section: Discussionsupporting

confidence: 92%

Identifying Risk Factors and Predicting Long COVID in a Spanish Cohort

Teruel,

Andreu,

Reina

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…The immunization (infection and vaccination) results for each person are shown as a timeline (measurements 1-39), presented in five diagrams for each figure (1,2,3,4,5). The diagrams are presented as follows: A logarithmic representation of all three antibody concentrations can be seen in Figures 1c, 2c, 3c, 4c, and 5c.…”

Section: Resultsmentioning

confidence: 99%

A New Set-up of Vanishing Antibodies: A Biennial Follow-up of Five Different Clients’ Humoral Responses Against Sars-Cov-2 After Systemic Vaccination in an Oncology Hospital in Poland

Kosiorek¹,

Stróż²,

Hryniewicz³

et al. 2022

Preprint

View full text Add to dashboard Cite

The humoral response of the COVID-19 vaccine varies from person to person. It largely depends on prior SARS-CoV-2 infection, obtaining an adequate immune response, and leaving a trace of changing antibody concentration over time. We retrospectively analyzed five clinical cases from selected patients and employees of the oncology hospital. All mild COVID-19 convalescents received the BNT162b2-Comirnaty mRNA vaccine three or four times. The levels of SARS-CoV-2 IgM- and IgG-specific antibodies, as well as S-RBD antibodies, were analyzed for two years. The concentration of antibodies was assessed in the laboratory using the chemiluminescent immunoassay CLIA, MAGLUMI. Results: (1) Active autoimmune disease stabilized the level of IgG-specific antibodies after systemic mRNA vaccination for at least six months. (2) Post-vaccination IgG and S-RBD levels decreased when vaccination was performed within three months of onset. (3) The booster dose administered only increased the S-RBD antibody levels. Declining IgG-specific antibodies were observed. (4) The S-RBD IgG levels were not correlated with the SARS-CoV-2 IgG levels in the vaccinated convalescents. (5) Subsequent reinfection with SARS-CoV-2 after vaccination three times released a more significant specific antibody response. Based on the collected data, we suggest that monitoring S-RBD antibodies is sensitive but not equivalent to a specific humoral response for SARS-CoV-2 IgG. We suggested that administering at least three doses of the mRNA vaccine should serve as the basis for immunization. The three-month interval may be the best alternative to an immunization schedule for non-immunocompromised people.

show abstract

“…Acute COVID-19 infection can cause a cytokine storm that leads to acute respiratory failure (ARDS) and death [2], while severe inflammatory disease can result in chronic polymyositis syndrome in children (PIMS) [3]. Almost half (44.8%) of symptomatic infections in children and adults manifest as varied symptoms related to chronic infection, in the form of long-COVID/post-COVID clinical syndrome, cognitive and physical deficits, pulmonary fibrosis, myocarditis, or neurological deficits [4,5]. The findings so far show that to acquire antiviral immunity to SARS-CoV-2, one does not need to come into contact with the virus and become infected [6].…”

Section: Introductionmentioning

confidence: 99%

A New Set-up of Vanishing Antibodies: A Biennial Follow-up of Three Different Clients’ Humoral Responses Against Sars-Cov-2 After Systemic Vaccination in an Oncology Hospital in Poland

Kosiorek¹,

Stróż²,

Hryniewicz³

et al. 2022

Preprint

View full text Add to dashboard Cite

The humoral response of the COVID-19 vaccine varies from person to person. It largely depends on prior SARS-CoV-2 infection, obtaining an adequate immune response, and leaving a trace of changing antibody concentration over time. We retrospectively analyzed three clinical cases from selected patients and employees of the oncology hospital. All mild COVID-19 convalescents received the BNT162b2-Comirnaty mRNA vaccine three times. The levels of SARS-CoV-2 IgM- and IgG-specific antibodies, as well as S-RBD antibodies, were analyzed for approximately two years. The concentration of antibodies was assessed in the laboratory using the chemiluminescent immunoassay CLIA, MAGLUMI. Results: (1) Active autoimmune disease stabilized the level of IgG-specific antibodies after systemic mRNA vaccination for at least six months. (2) Post-vaccination IgG and S-RBD levels decreased when vaccination was performed within three months of onset. (3) The booster dose (third dose) administered only increased the S-RBD antibody levels. Declining IgG-specific antibodies were observed. (4) The S-RBD IgG levels were not correlated with the SARS-CoV-2 IgG levels in the vaccinated convalescents. (5) Subsequent reinfection with SARS-CoV-2 after vaccination three times released a more significant specific antibody response. Based on the collected data, we suggest that monitoring S-RBD antibodies is sensitive but not equivalent to a specific humoral response for SARS-CoV-2 IgG. We suggested that administering at least three doses of the mRNA vaccine should serve as the basis for immunization. The three-month interval may be the best alternative to an immunization schedule for non-immunocompromised people.

show abstract

Correction to: Long COVID in children and adolescents

Abstract: One of the co-authors of this article has changed her name due to her personal reason. Fateme Sasannia should be changed to Sarvin Sasannia.Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Cited by 5 publications

References 0 publications

Identifying Risk Factors and Predicting Long COVID in a Spanish Cohort

Identifying Risk Factors and Predicting Long COVID in a Spanish Cohort

A New Set-up of Vanishing Antibodies: A Biennial Follow-up of Five Different Clients’ Humoral Responses Against Sars-Cov-2 After Systemic Vaccination in an Oncology Hospital in Poland

A New Set-up of Vanishing Antibodies: A Biennial Follow-up of Three Different Clients’ Humoral Responses Against Sars-Cov-2 After Systemic Vaccination in an Oncology Hospital in Poland

Contact Info

Product

Resources

About